Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

UPA Maglira 5 - 5mg pen

R 1,250.00
Add to WishlistCompare

Maglira 5 — Semaglutide Pre-Filled Pen

Metabolic Health | Appetite Regulation | Weight-Management Research

Product Overview

Maglira 5 is a pre-filled pen labelled as containing semaglutide, a GLP-1 receptor agonist studied extensively for its role in appetite regulation, blood-glucose control and body-weight management.

Semaglutide mimics the activity of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose regulation and appetite signaling. Its effects on these pathways have made it an important focus of clinical research into obesity, type 2 diabetes and associated metabolic health outcomes.

Key Clinical Research Findings

1. Significant Body-Weight Reduction

The landmark STEP 1 clinical trial, published in The New England Journal of Medicine, evaluated once-weekly semaglutide 2.4 mg in adults with overweight or obesity without diabetes.

After 68 weeks, participants receiving semaglutide alongside lifestyle intervention experienced an average body-weight reduction of 14.9%, compared with 2.4% in the placebo group.

Additionally, 50.5% of participants receiving semaglutide achieved at least 15% weight reduction, compared with 4.9% of participants receiving placebo.

These findings demonstrate the potential of semaglutide in the studied population. They are not a prediction of results from Maglira 5.

2. Appetite Regulation and Energy Intake

Semaglutide acts on GLP-1 receptors involved in appetite signalling and food intake. Clinical research has demonstrated that treatment with studied semaglutide formulations can reduce energy intake and support sustained body-weight reduction.

Individual outcomes vary, and these findings should not be interpreted as a guarantee of appetite suppression or weight loss with this specific product.

3. Blood-Glucose Regulation

Semaglutide has demonstrated improvements in glycaemic control in clinical trials involving people with type 2 diabetes. It supports glucose regulation through glucose-dependent effects on insulin secretion and other GLP-1-related mechanisms.

The extent of these effects depends on the formulation, clinical indication and individual circumstances.

4. Cardiometabolic Health Markers

In STEP 1, semaglutide treatment was associated with improvements in several measured cardiometabolic risk factors, including waist circumference, blood pressure, glycated haemoglobin and lipid measurements.

These findings support continued research into semaglutide's role in metabolic health. Improvements in individual markers do not necessarily translate into identical clinical outcomes for every person or product.

Key Features

Key Features


  • Prefilled precision injection pen

  • Contains 2.5 mg Citate Weekly Injection

  • Ready-to-use design

  • Accurate click-dose adjustment

  • Pharmaceutical-grade manufacturing

  • Convenient storage and handling

  • Designed for consistency and reliability

  • Professional laboratory presentation
Dosage & Usage

Maglira 5 — Click/Dosage Information Printed on the Box

15 clicks = 0.25 mg

30 clicks = 0.5 mg

45 clicks = 0.75 mg

60 clicks = 1.0 mg



FAQ's & Tips

1. What is Maglira 5?

Maglira 5 is a prefilled pen containing a 2.5 mg formulation designed for scientific and laboratory research. The integrated pen format offers a convenient presentation for research environments where standardized delivery systems are being evaluated.

2. What is Maglira 5 used for in research?

Published scientific research involving this class of compounds has explored areas including metabolic regulation, appetite signalling, glucose homeostasis, gastric emptying, and body weight. Research continues to investigate additional applications across metabolic science.

3. What type of product is Maglira 5?

Maglira 5 is supplied as a prefilled pen, eliminating the need for separate preparation or reconstitution before research use.

4. What are the advantages of a prefilled pen?

Prefilled pen systems provide a convenient, ready-to-use format and are commonly selected in research settings where consistency, handling efficiency, and standardized presentation are important considerations.

5. Does Maglira 5 require reconstitution?

No. Maglira 5 is supplied in a prefilled pen format and does not require reconstitution before use in laboratory research.

6. How should Maglira 5 be stored?

Maglira 5 should be stored according to the manufacturer's storage recommendations. Refrigerated storage is typically recommended unless otherwise specified on the product packaging.

7. Is Maglira 5 manufactured to pharmaceutical standards?

Maglira 5 is presented in a professionally manufactured prefilled pen designed to support consistency and quality for research applications.

8. What areas of research involve compounds like Maglira 5?

Scientific literature has investigated this class of compounds in relation to:


  • Metabolic regulation

  • Glucose homeostasis

  • Appetite signalling

  • Energy balance

  • Weight management research

  • Cardiometabolic health

  • Endocrine function

9. Why is a weekly formulation commonly studied?

Long-acting formulations are frequently evaluated because they provide sustained biological activity over extended periods, allowing researchers to investigate long-term physiological effects.

10. Is Maglira 5 intended for laboratory research?

Yes. Maglira 5 is supplied for scientific and laboratory research purposes. Researchers should consult published literature and institutional protocols when designing studies.

11. What makes Maglira 5 different from vial-based products?

Unlike traditional vial-based products, Maglira 5 is supplied in a prefilled pen, offering a ready-to-use presentation without requiring separate preparation.

12. Where can I find research relating to compounds like Maglira 5?

Peer-reviewed studies can be found in scientific journals such as:


  • The New England Journal of Medicine

  • JAMA

  • Nature Reviews Endocrinology

  • Diabetes Care

These publications provide detailed methodology and research findings.

13. What should researchers consider when reviewing published studies?

Researchers commonly evaluate:


  • Study design

  • Experimental model

  • Sample size

  • Duration

  • Outcome measures

  • Statistical analysis

  • Reported limitations

  • Long-term follow-up data

14. Can Maglira 5 be used alongside other research compounds?

The compatibility of compounds depends on the objectives and design of individual research studies. Published literature should be reviewed when evaluating combination research protocols.

15. Why choose Maglira 5 from Health-Tech?

Health-Tech focuses on supplying premium research products supported by professional presentation, educational resources, and scientifically referenced content to assist researchers in evaluating published literature.

Research

Maglira 5 is supplied in a prefilled pen format designed to support laboratory and scientific research involving its active compound. The integrated delivery system provides a standardized presentation suitable for research environments where consistency and reproducibility are important.

Current scientific literature has investigated this class of compounds for their effects on metabolic regulation, glucose homeostasis, appetite signaling, gastric emptying, and body weight. Research continues to evaluate their potential across a range of metabolic and endocrine applications.

Areas of Scientific Investigation

Published research has explored this class of compounds in relation to:


  • Appetite regulation

  • Energy balance

  • Body weight management

  • Glucose metabolism

  • Insulin secretion

  • Glucagon regulation

  • Gastric emptying

  • Cardiometabolic health

  • Metabolic syndrome

  • Obesity-related research

Research Considerations

When evaluating findings within the scientific literature, researchers commonly consider factors such as:


  • Study duration

  • Experimental model

  • Dosage regimen used within the study

  • Primary and secondary outcome measures

  • Biomarker assessment

  • Safety observations

  • Statistical significance

  • Long-term follow-up data where available

Interpretation of study findings should always consider the methodology and limitations reported by the original investigators.

Scientific Literature

Examples of peer-reviewed research relating to this therapeutic class include:


  • Effects on glycaemic regulation in metabolic disease

  • Appetite signalling through GLP-1 receptor pathways

  • Weight management outcomes in controlled clinical research

  • Cardiovascular outcomes associated with GLP-1 receptor agonists

  • Long-term metabolic effects reported in multicentre clinical trials

Researchers are encouraged to consult the original peer-reviewed publications for detailed methodology and complete study results.

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

Rubino D, et al. Effect of Continued Weekly Semaglutide on Weight Maintenance. JAMA. 2021.

Davies M, et al. Semaglutide 2.4 mg Once Weekly in Adults with Overweight or Obesity. Nature Reviews Endocrinology.

American Diabetes Association. Standards of Care in Diabetes.

Disclaimer

This information is provided solely for educational and scientific reference purposes. It summarizes published research and should not be interpreted as clinical guidance or instructions for use. Researchers should consult the original peer-reviewed literature and applicable institutional protocols when evaluating published findings.

Reviews